Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MenACYW versus Nimenrix in toddlers aged 12 to 23 months
2016-000749-30Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of Meningococcal ACWY conjugate vaccine and Meningococcal polysaccharide vaccine group W-135 in meningococcal disease (2 arms), sponsored by Sanofi. Primary endpoint: Seroprotection rate by hSBA at Day 30. Started Oct 2016; status: completed.
02
Drugs
Meningococcal ACWY conjugate vaccineMeningococcal polysaccharide vaccine group W-135
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on 2016-000749-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000749-30.